Key Stats for Thermo Fisher Stock
- Current Price: $449.37
- TIKR Target Price (Mid): ~$703
- Street Mean Target: ~$612
- Potential Total Return: ~56%
- Annualized IRR: ~10% / year
- Most Recent Earnings Reaction: +0.64% (4/23/26)
- Max Drawdown: 31.45% (5/15/26)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Thermo Fisher Scientific (TMO) held its 2026 Investor Day in New York on May 20, and the gap between what management presented and where the stock trades captures the entire debate around this name.
The stock closed at $449.37 the following day, 31.45% below its 52-week high of $643.99 after hitting its max drawdown low on May 15. Academic and government funding remains suppressed, the $8.875 billion Clario acquisition closed just two months ago, and Q1 organic growth came in at 1%. Against that, CEO Marc Casper and CFO Jim Meyer spent six hours in New York making the case that the pain is temporary and the structural opportunity ahead is the largest in the company’s 20-year history.
The Recovery Roadmap and Why the Sequencing Matters
The Investor Day reaffirmed a 7% long-term organic revenue CAGR, targeting a return to that run rate by 2028 after a guided 3%–6% range through 2026 and 2027. CFO Jim Meyer confirmed 8%–10% adjusted EPS growth for 2026, with 40–50 basis points of annual operating margin expansion and low-teens adjusted EPS and free cash flow growth targeted over the long term.
The most telling comment came in Q&A. “Our end markets are incredibly predictable,” Casper said. “We’ve had the benefit of three quarters since then, and the markets have actually played out exactly as we’ve expected to.” It is a specific claim: the recovery sequence is tracking pharma and biotech stabilizing first, biotech research spending second, and academic and government last.
Where each piece stands today:
Pharma and biotech (57% of revenue, moving toward 60%) is already improving. Pharma services capacity that Thermo Fisher has already contracted out is coming online over the next several quarters, giving Meyer “great visibility” into the back half of 2026 and 2027. The more than $500 billion in announced U.S. domestic pharma manufacturing investment is monetizing through the CDMO business now, not just in future projections.
Electron microscopy for semiconductor fabs already more than 3% of company revenue is another identified engine as AI-driven chip investment accelerates demand for automated in-line quality control.
Academic and government remains the weak leg. The NIH budget passed with a slight increase and funding flow improved at the end of Q1, but Meyer’s base case keeps normalization as a 2027 story. Casper flagged China (7.5% of revenue) as a potential upside not embedded in the model, with pharma and biotech growing well there despite pressure in industrial and diagnostics.
See historical and forward estimates for Thermo Fisher stock (It’s free!) >>>
Three Disclosures That Deserved More Attention
Reshoring is already generating revenue. Business unit leader Michael Shafer described a top-ten pharma customer running three simultaneous tracks with Thermo Fisher today: validating the new DynaDrive single-use bioreactor platform in design centers, transferring existing drug programs into U.S. CDMO capacity for immediate GMP production, and planning tech transfers for their new domestic facility. “We’re actually already winning new business, significant new business for our CDMO because people are moving programs into our capacity right now,” Shafer said. Thermo Fisher also acquired a sterile fill-finish facility in New Jersey to capture near-term demand from these transfers.
Clario is more than a revenue deal. The $8.875 billion acquisition of Clario, closed March 24, brought a business that generated $1.25 billion in revenue last year, is currently active on more than 30,000 clinical trials globally, and underpins 70% of FDA and EMA-approved medicines over the past decade. In 2026, Clario adds $0.32 of adjusted EPS across nine months of ownership and approximately 20 basis points of margin. The $175 million adjusted operating income synergy target by year five is primarily revenue-driven. Clario’s endpoint data integrates with Thermo Fisher’s CRO, CDMO, and clinical supply workflows, creating what management calls “accelerator drug development.” No standalone CRO or CDMO offers this.
The NVIDIA partnership is a product launch, not a roadmap item. Gianluca Pettiti confirmed that the collaboration will produce “the first version of fully autonomous instruments being deployed to our customers in the second half of the year.” Combined with Thermo Fisher’s OpenAI collaboration on clinical trial design, the company is positioning its instruments and services as the physical infrastructure layer for AI-driven drug development.
Is the Discount Justified?
At 16.34xNTM EV/EBITDA and 17.68x NTM P/E, Thermo Fisher trades near a multi-year valuation low. The NTM EV/EBITDA multiple peaked at 21.22x at the end of 2025 and has compressed steadily since, as academic demand disappointed.
Peers with narrower capabilities trade at comparable or higher multiples. Waters Corporation (WAT), a focused analytical instruments company, trades at 16.88x NTM EV/EBITDA and 22.70x NTM P/E. Lonza Group (LONN), Thermo Fisher’s direct competitor in bioproduction and CDMO, trades at 16.74x NTM EV/EBITDA and 27.08x NTM P/E. IQVIA (IQV), the largest standalone CRO, trades at 10.41x NTM EV/EBITDA and 12.79x NTM P/E.
Thermo Fisher sits at a discount to both Waters and Lonza despite operating across instruments, bioproduction, CDMO, and CRO simultaneously. That breadth is the source of the economic moat. Casper described the ability to follow a biotech customer from early proteomics research all the way through Phase III and commercial manufacturing. At 16.34x, investors are not paying peak valuation multiples for that capability stack.
Of the analysts covering TMO, 19 rate it Buy, 5 Outperform, and 3 Hold, with zero Underperforms or Sells. The Street’s mean target of $611.56 implies around 36% upside from the current price, based on a recovery timeline management insists is already on track.
See how Thermo Fisher performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $449.37
- Target Price (Mid): ~$703
- Potential Total Return: ~56%
- Annualized IRR: ~10% / year
See analysts’ growth forecasts and price targets for Thermo Fisher stock (It’s free!) >>>
TIKR’s mid-case model uses the mid-scenario assumptions from the valuation tool: revenue CAGR of around 5% through 2030, with net income margins expanding toward approximately 21%.
The two primary revenue drivers are pharma and biotech (bioproduction reshoring contracts ramping, Clario accelerating CRO authorizations) and analytical instruments (semiconductor electron microscopy, autonomous instrument deployment). The margin driver is the PPI Business System compounding with AI-enabled productivity. CFO Meyer sized this at approximately $80 million to $100 million of incremental annual productivity above Thermo Fisher’s historical norms.
The upside case is faster academic recovery and China pharma/biotech outperforming model assumptions, both flagged by Casper as potential positives not in current guidance. The downside risk is Clario’s earn-out milestones missing in 2026 or 2027, and organic growth slipping below the 3%–4% guided range if the pharma services back-half ramp is delayed.
At around $449, TIKR’s mid-case implies approximately 56% total return through 12/31/30, or around 10% annualized return profile of a wide-moat compounder trading at a meaningful discount while the market waits for an end-market recovery management says is already tracking on schedule.
Conclusion
The thesis confirmation will not come from an Investor Day. It will come in late July when Thermo Fisher reports Q2 results. Watch for organic revenue growth landing at or above 3%, which would confirm that the pharma services back-half ramp is on track, and watch for management to hold full-year adjusted EPS guidance of $24.64 to $25.12.
The NVIDIA autonomous instrument launch is the near-term wildcard. Pettiti is committed to a second-half 2026 deployment. If commercial units ship on time with strong early customer response, the multiple could begin re-rating before the fundamental recovery shows up fully in the numbers.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Thermo Fisher?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Thermo Fisher, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Thermo Fisher alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Thermo Fisher on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
